WaveMan
WaveMan · Company
KNSA · Kiniksa Pharmaceuticals International, Plc
> Search tickers & screens ⌘K
LIVE
← All companies

KNSA Kiniksa Pharmaceuticals International (KNSA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001730430
Quote by TradingView
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
155
13F, latest reported quarter
Conversions, 180 days
34
Codes C/M, not in net · $2.1M priced

What the filings say about KNSA

Insiders, 180 days
-$6.5M net sold
4 sellers · 20% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$6.0M
3 notices

Kiniksa Pharmaceuticals International insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Kiniksa Pharmaceuticals International, plc insiders sold a net $6.5M of stock across 153 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Megna Michael R
CHIEF ACCOUNTING OFFICER
SELL
2026-09-03 SEC
4,600
$369.4K
-6.3%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Apr 9, 2026.
  • The trade is 15.8% of the 29,062 shares held after it.
  • No other insider sold within 30 days.
  • 155 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF ACCOUNTING OFFICER Megna Michael R sold about $369.4K of KNSA under a 10b5-1 plan on Sep 3, 2026; 155 funds added in the latest 13F quarter.
Cole G Bradley
Director
SELL
2026-07-31 SECtraded 2026-07-29
3,673
$299.1K
-0.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 31.5% of the 11,672 shares held after it.
  • No other insider sold within 30 days.
  • 155 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Cole G Bradley sold about $299.1K of KNSA on Jul 29, 2026; 155 funds added in the latest 13F quarter.
Paolini John F.
CHIEF MEDICAL OFFICER
SELL
2026-05-05 SECtraded 2026-05-01
37,327
$2.0M
+25.3%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Mar 2, 2026.
  • The trade is 43.0% of the 86,720 shares held after it.
  • 4 other insiders sold within 30 days.
  • 155 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF MEDICAL OFFICER Paolini John F. sold about $2.0M of KNSA on May 1, 2026; 4 other insiders sold within 30 days and 155 funds added in the latest 13F quarter.
Paolini John F.
CHIEF MEDICAL OFFICER
SELL
2026-05-05 SECtraded 2026-05-01
21,097
$1.1M
+25.3%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Mar 2, 2026.
  • The trade is 32.1% of the 65,623 shares held after it.
  • 4 other insiders sold within 30 days.
  • 155 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF MEDICAL OFFICER Paolini John F. sold about $1.1M of KNSA on May 1, 2026; 4 other insiders sold within 30 days and 155 funds added in the latest 13F quarter.
Patel Sanj K
CHAIRMAN & CEO
SELL
2026-05-01 SEC
48,565
$2.6M
+26.7%
Context
  • 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on Apr 30, 2026.
  • 4 other insiders sold within 30 days.
  • 155 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHAIRMAN & CEO Patel Sanj K sold about $2.6M of KNSA on May 1, 2026; 4 other insiders sold within 30 days and 155 funds added in the latest 13F quarter.
153 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 148 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$6.5M over 180 days
-$668.5K over 90 days
below 81% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
155 funds bought in last quarter
more than 84% of Pharma & Biotech
Revenue
+60.1% year over year
more than 79% of Pharma & Biotech
Margin
8.7% net margin
more than 81% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
9.5% of the float short (float per yahoo 2026-10-26) · 6.4 days to cover · settled 2026-09-30
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch KNSA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+88.2%12M
-5%+35%+75%+115%2025-102025-122026-022026-042026-062026-082026-10 2026-04-28 · Patel Sanj K sold $12.7M2026-04-28 · Patel Sanj K sold $5.9M2026-04-28 · Patel Sanj K sold $3.8M2025-10-31 · Paolini John F. sold $3.1M2026-04-28 · Patel Sanj K sold $2.8M2026-05-01 · Patel Sanj K sold $2.6M2026-05-01 · Paolini John F. sold $2.0M2025-12-08 · Ragosa Mark sold $1.8M2026-04-29 · Patel Sanj K sold $1.2M2026-05-01 · Paolini John F. sold $1.1M2026-03-02 · Paolini John F. sold $997.4K2026-03-09 · Ragosa Mark sold $866.6K2025-12-15 · Quart Barry D sold $835.6K2026-03-09 · Ragosa Mark sold $819.6K2025-11-12 · Ragosa Mark sold $814.7K2026-04-28 · Quart Barry D sold $656.3K2026-02-03 · Quart Barry D sold $567.1K2026-03-02 · Paolini John F. sold $533.2K2026-01-08 · Ragosa Mark sold $502.7K2025-12-15 · Tessari Eben sold $500.7K2025-11-17 · Tessari Eben sold $488.4K2026-02-09 · Ragosa Mark sold $390.5K2026-02-09 · Ragosa Mark sold $381.7K2026-09-03 · Megna Michael R sold $369.4K2026-04-06 · Patel Sanj K sold $364.0K2026-04-06 · Quart Barry D sold $345.1K2026-04-09 · Megna Michael R sold $309.3K2026-07-29 · Cole G Bradley sold $299.1K2026-03-02 · Paolini John F. sold $262.4K2026-02-12 · Quart Barry D sold $121.0K2026-02-04 · Quart Barry D sold $117.1K2026-04-30 · Patel Sanj K sold $115.6K2026-04-06 · Moat Ross sold $115.0K2026-04-09 · Moat Ross sold $79.5K2026-02-02 · Quart Barry D sold $37.4K2025-11-17 · Tessari Eben sold $25.9K2025-11-26 · Tessari Eben sold $8.6K2026-02-10 · Quart Barry D sold $5.0K2025-10-28 · Ragosa Mark sold $4.1K2026-09-03 · Megna Michael R filed to sell $369.4K2026-07-29 · Cole G Bradley filed to sell $299.1K2026-07-29 · Tessari Eben filed to sell $5.3M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns KNSA: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
6,971,361 sh
$445.8M
Rubric Capital Management LP
3,999,800 sh
$255.8M
BAKER BROS. ADVISORS LP
2,834,643 sh
$181.3M
BlackRock, Inc.
2,739,615 sh
$175.2M
TANG CAPITAL MANAGEMENT LLC
2,259,889 sh
$144.5M

Congress trades in KNSA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

KNSA planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Megna Michael R
Filed 2026-09-03
$369.4K
Cole G Bradley
Filed 2026-07-29
$299.1K
Tessari Eben
Filed 2026-07-29
$5.3M

KNSA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Oberweis Micro-Cap Fund
$24.9M position · as of 2026-06-30
1.5%
JAMES MICRO CAP FUND
$441.8K position · as of 2026-06-30
1.3%
Driehaus Micro Cap Growth Fund
$7.2M position · as of 2026-06-30
1.2%
LISANTI SMALL CAP GROWTH FUND
$223.8K position · as of 2026-06-30
1.2%
Inspire Fidelis Multi Factor ETF
$1.9M position · as of 2026-05-31
0.9%
Invesco Small Cap Growth Fund
$16.0M position · as of 2026-06-30
0.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 2
1 active
1
Not applicable
1 active
2
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Sanj K. Patel
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$10.8M
$28.4M
$3.5M
+133%
+25%
2024
$7.0M
$8.7M
$2.4M
+12%
-9%
2023
$5.3M
$6.8M
$1.8M
-1%
-8%
2022
$6.1M
$8.7M
$1.9M
-15%
-11%
2021
$6.6M
$579.5K
$1.7M
-33%
-1%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $6.5M sold by insiders over 180 days, 155 funds added last quarter, $6.0M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

KNSA financials

Revenue growth
+60.1%
XBRL, annual
Net margin
8.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$754.0M
four quarters, 2025-04-01 to 2026-03-31
Net margin, TTM
+9.7%
net income over revenue, 2025-04-01 to 2026-03-31
Free cash flow, TTM
$164.2M
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
+13.7%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets
+10.3%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on invested capital
n/a
no debt line filed
Return on capital employed
+15.9%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
P/E, trailing
80.20x
close 2026-10-26 over four quarters of diluted EPS, 2025-04-01 to 2026-03-31
Enterprise value
n/a
no share count filed
FCF yield
n/a
no share count filed
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$677.6M$423.2M$270.3M$220.2M
Operating income$77.2M-$45.6M-$25.2M$9.8M
Net income$59.0M-$43.2M$14.1M$183.4M
EPS (diluted)0.75-0.600.202.60
Operating cash flow$138.0M$25.7M$13.3M$5.8M
Cash$165.6M$183.6M$108.0M$122.7M
SEC XBRL, fiscal years, as known on 2026-10-28

KNSA Stock Sonar score 5/7 axes

Find similar shapesCompare

KNSA ranks highest on profitability (90th percentile) and institutional and government (84th), and lowest on insider conviction (9th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
90
Inputs
  • Return on equity+13.7% · 86 pct, sector of 545
  • Return on assets+10.3% · 89 pct, sector of 691
  • Return on invested capitalno debt line filed
  • Return on capital employed+15.9% · 93 pct, sector of 576
Growth
79
Inputs
  • Revenue growth, YoY+60.1% · 79 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
9
Inputs
  • Net Form 4 buying (codes P and S), 180d-$6.2M · 18 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
84
Inputs
  • Funds adding, latest quarter155 · 84 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
41
Inputs
  • Short interest, % of float+9.5% · 41 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

KNSA filings, in plain words

Are Kiniksa Pharmaceuticals International insiders buying or selling KNSA?

In the 180 days to 2026-10-28, Kiniksa Pharmaceuticals International insiders were net sellers, a net $6.5M across purchases and sales reported on Form 4, by 4 sellers.

Are there planned insider sales of KNSA?

Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $6.0M of stock; the latest, by Megna Michael R, was filed 2026-09-03.

Read the full summary

In the 180 days to 2026-10-28, Kiniksa Pharmaceuticals International insiders were net sellers of KNSA, a net $6.5M across purchases and sales reported on Form 4 by 4 sellers. 20% of the 5 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $6.0M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies